Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQF3250 in healthy adult subjects
NCT07327281Phase 1Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TQF3250 in hyperglycemia, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Adverse Events at 20 days, Clinical laboratory test indicators at 20 days and 6 more. Started Dec 2025; status: recruiting.
02
Drugs
TQF3250
03
Conditions
hyperglycemia
Beyond the preview
Go deeper on NCT07327281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07327281.